Vaccibody and Ultimovacs nominated to DNB HealthCare Prize on 1 MNOK

DNB wants to contribute to a growth industry in Norway and has established a healthcare prize for early stage healthcare companies within pharmaceuticals, biotech, medtech and diagnostics. Of the six nominated for the DNB HealthCare Prize on 1 MNOK, two of them are members of the Oslo Cancer Cluster: Vaccibody and Ultimovacs. The other nominees are: Spiro Medical, Glucoset, Picterus and Labrida.

The winner will be announced and given the prize money by Rune Bjerke, CEO of DNB at the DNB Healthcare Conference on December 15. Companies will be evaluated on their business potential, innovation capacity and ability to execute. The prize is NOK1m and the six finalists will each hold a six-minute pitch for the jury and the audience. You are invited to vote for your favourite candidate.




Print This Post